News related to
Microsoft

Empowering SMEs and Working Professionals to Embrace AI and Foster Widespread AI Adoption in Hong Kong

HONG KONG SAR – Media OutReach Newswire – 28 August 2026 – The Hong Kong Productivity Council (HKPC) today held the Launching Ceremony of the “AI for All” Inclusive Programme, aligning with the National 15th Five-Year Plan and the “AI+” initiative, and supporting the HKSAR Government’s policies of “industries for AI, AI for industries” and “AI for All”. Coordinated by the Innovation, Technology and Industry Bureau (ITIB), the “AI for All” Inclusive Programme aims to promote the widespread adoption of AI across society. As one of the programme implementation partners, HKPC will lead the “AI with HKPC – Business Empowerment” sub-programme, focusing on practical business applications, talent development, and inclusive technology adoption. The initiative will provide targeted support to SMEs, professionals, labour groups, and underprivileged communities through a range of training courses, hands-on application programmes, and industry-academia-research collaboration, promoting AI literacy and the practical deployment of AI technologies.

Professor SUN Dong, JP, Secretary for Innovation, Technology and Industry, officiated at the ceremony, joined by Mr Emil YU Chen-on, BBS, JP, Deputy Chairman of HKPC, and Mr Mohamed Butt, MH, Executive Director of HKPC. The event also brought together representatives from leading international and Chinese Mainland technology enterprises, chambers of commerce, and industry leaders, who shared successful case studies and practical insights, fostering collaboration across sectors to advance Hong Kong’s AI ecosystem.

Professor SUN Dong, JP, Secretary for Innovation, Technology and Industry, said: “AI has become a key factor in global industrial upgrading and driving the development of the digital economy. Helping SMEs to achieve digital transformation and enhance competitiveness through AI is one of the focal points of the ‘AI for All’ inclusive programme. This time, HKPC as the third implementing organisation for the ‘AI for All’ inclusive programme, leverages its years of experience serving businesses to provide targeted and professional support to SMEs, helping them seize opportunities in the AI era. I hope that through the ‘AI for All’ inclusive programme, AI will not only serve as an empowering tool to enhance corporate value and competitiveness but also transform into a super dividend that benefits SMEs and the general public. Let ‘AI for All’ become Hong Kong’s vision for ‘Upgrading for All’ and ‘Opportunities for All’.”

Mr Emil YU Chen-on, BBS, JP, Deputy Chairman of HKPC, said: “AI should not be a privilege reserved for large enterprises. It should become a productivity tool that every business, every employee, and people from all walks of life can leverage. HKPC has long been committed to helping enterprises, particularly SMEs, enhance productivity, drive digital transformation, and convert innovative technologies into tangible business value. We focus on integrating AI technologies across different industries by providing practical, scalable and replicable solutions that support smart transformation. As one of the implementation organisations of the ‘AI for All’ Inclusive Programme, HKPC will centre its efforts on ‘AI with HKPC – Business Empowerment’, connecting Government, industry, academia, technology partners and social service organisations to help enterprises, SMEs, professionals and underprivileged communities acquire AI capabilities and transform AI into real productivity and business value, thereby advancing Hong Kong’s high-quality development and digital inclusion.”

“AI for All” Officially Launches with “Business Empowerment” Series to Drive Widespread AI Adoption

To advance the “AI for All” Inclusive Programme, HKPC has launched the “AI with HKPC – Business Empowerment” training series, centred on practical business applications. Through a two-year training and promotion programme, HKPC will work with technology companies, chambers of commerce, labour groups and community partners to help SMEs, professionals, working individuals, labour organisations, underprivileged groups and the general public acquire AI knowledge and application skills. The initiative aims to accelerate the adoption of AI and support digital and smart transformation across industries, sectors and communities through three key focus areas:

1. Business and Industry Upgrading: Through AI-focused programmes such as “AI+ Industry Boost Training” and “SME AI Connect”, enterprises can rapidly adopt AI technologies to enhance productivity and competitiveness. Key training topics include:

• Practical Applications of Generative AI: Learning how to use generative AI tools for content creation, data analysis, and workflow optimisation.
• AI Applications Across Industries: Exploring how AI enhances efficiency, optimises operations and drives innovation in sectors including education, healthcare, manufacturing, retail and logistics.
• AI Project Workshops: Providing hands-on experience in AI application development and implementation, enabling participants to integrate AI solutions into real business scenarios.

2. Human Resources and Leadership: HKPC will continue conducting the “Hong Kong Enterprise AI Application Trends Survey” and share insights through “AI Talent Winning Tips”, helping organisations understand AI talent management and application trends while preparing for future workforce needs. Key topics include:

• AI and Career Development: Examining the impact of AI on the future workplace and helping professionals understand emerging skills requirements.
• AI Talent Management and Application Strategies: Sharing successful corporate experiences and practical strategies for AI transformation and talent development.

3. AI for ALL: Through the free online learning platform “AI BiteClass”, HKPC will provide convenient AI learning resources for SMEs, professionals, senior citizens and underprivileged communities, enabling people from all backgrounds to access AI fundamentals and the latest application trends anytime, anywhere. Key topics include:

• Introduction to AI Fundamentals: Covering basic AI concepts, operating principles, common use cases and future trends.
• Getting Started with Generative AI: Introducing generative AI tools and their everyday applications.
• AI Ethics and Responsible Use: Building awareness of responsible AI adoption, including issues relating to data privacy, bias and transparency.

“AI BiteClass” Debuts at Launch Ceremony, Bringing Global Technology Expertise to Hong Kong

As part of the launch event, HKPC presented a live edition of the “AI BiteClass”, featuring experts from HKPC and leading global technology companies, including Amazon Web Services (AWS), Google Cloud, Huawei Cloud, Lenovo, Samsung, Tencent Cloud and Microsoft. The sessions shared practical AI techniques and real-world application cases tailored for SMEs. Through concise yet insightful presentations, the guest speakers highlighted the best practices and implementation strategies for AI, demonstrating how businesses can leverage AI to drive growth and enhance operational efficiency.

Looking ahead, the “AI BiteClass” will introduce a range of free online courses covering popular topics such as generative AI, AI agents, workflow automation, data analytics and enterprise transformation. Members of the public will be able to access practical AI learning resources at any time through the online platform or via iAM Smart.

HKPC has long positioned itself as a “technology adopter and enabler”, committed to helping enterprises transform innovation into tangible business value. Since 2024, HKPC has organised more than 600 AI training sessions, serving over 32,000 participants, including SMEs, large enterprises, HR professionals, industry leaders, students, educators and members of the public. These efforts have played a pivotal role in fostering a more competitive AI application ecosystem in Hong Kong.

A series of “AI with HKPC – Business Empowerment” activities will be rolled out progressively. Enterprises and members of the public are welcome to register via iAM Smart and stay updated on the latest programmes. Through collaboration with global technology enterprises, industry organisations and community partners, HKPC aims to bring AI into businesses, workplaces and communities, advancing the vision of “AI for All” while empowering enterprises and co-building Hong Kong’s intelligent future. For details, please visit: https://www.hkpcacademy.org/en/aiforall/

Please download the high-res photos HERE.

Photo Captions:

1. Professor SUN Dong, JP, Secretary for Innovation, Technology and Industry of the HKSAR Government, delivers a speech at the ceremony, sharing the Government’s vision for advancing the “AI for All” Inclusive Programme, accelerating AI adoption and fostering innovation and technology development in Hong Kong.
2. Professor SUN Dong, JP, Secretary for Innovation, Technology and Industry of the HKSAR Government (middle), Mr Emil YU Chen-on, BBS, JP, Deputy Chairman of HKPC (left), and Mr Mohamed Butt, MH, Executive Director of HKPC (right) officiate the HKPC Launching Ceremony of the “AI for All” Inclusive Programme, jointly promoting AI literacy and application.
3. Mr Emil YU Chen-on, BBS, JP, Deputy Chairman of HKPC, says HKPC will help enterprises and talent master AI technologies through the “AI with HKPC – Business Empowerment” series, supporting the transition from AI awareness to practical application.
4. The “AI for All” Inclusive Programme attracts representatives from the business and innovation and technology sectors to explore the latest AI developments and application opportunities.
5. HKPC hosts an “AI BiteClass” sharing session on the day of the Launching Ceremony, inviting technology companies and industry experts to present practical AI experiences and success stories, helping enterprises enhance productivity and competitiveness through AI.

Hashtag: #HKPC

The issuer is solely responsible for the content of this announcement.

About the Hong Kong Productivity Council

The Hong Kong Productivity Council (HKPC) is a statutory body established in 1967, dedicated to enhancing the productivity and competitiveness of Hong Kong enterprises through world-class applied R&D, innovative technology services, and integrated manufacturing solutions. As a market-oriented, international R&D organisation, HKPC leverages its deep expertise and extensive industry experience in key areas such as AI, advanced manufacturing, life and health technology, green technology and new energy to drive new industrialisation and support the growth of emerging and future industries.

HKPC focuses on addressing businesses challenges and industrial technology needs, promoting the full integration between technological and industrial innovation. Through technology transfer, product innovation, intellectual property protection and commercialisation of R&D outcomes, the Council fosters collaboration with the local business community as well as top global R&D institutions, delivering added value to industries and advancing the development of new productive forces. HKPC’s world-class R&D achievements have been widely recognised over the years, winning an array of local and overseas accolades, reinforcing Hong Kong’s role as an international innovation and technology centre and a smart city.

To help enterprises capitalise on Hong Kong’s strengths in international connectivity to expand into global markets, HKPC offers comprehensive overseas expansion services tailored to critical areas including product development, technology, manufacturing, and management, enabling businesses to successfully go global from Hong Kong.

HKPC is also committed to providing timely and practical support to SMEs and startups with timely and practical , assisting them in accessing Government funding programmes. Through its FutureSkills training initiatives, HKPC helps both industry and academia stay ahead in latest digital and STEM technologies, nurturing a future-ready talent pool for Hong Kong.

For more information, please visit HKPC’s website: www.hkpc.org/en.

Packaging Empire was established in response to demand from businesses seeking one partner for both requirements. The Gift Empire has supplied customised corporate gifts and promotional gifts since 1999 to organisations including Amazon, Citibank, Maybank, Shopee, and Microsoft, and receives orders through GeBIZ, Ariba, and Coupa, the procurement systems used by Singapore government agencies and large corporate buyers. Accounts of that size have traditionally run separate vendors for promotional gifts and presentation packaging, which adds cost and complicates delivery schedules when both elements are tied to the same campaign date.

The division produces gift boxes, mailer boxes, retail packaging, product sleeves, and event packaging, covering product launches, corporate events, gift-with-purchase campaigns, festive gifting, roadshows, retail applications, and brand activations. Demand for everyday corporate gift items such as custom canvas tote bags and custom water bottles in Singapore has grown alongside the shift, and these are frequently ordered with matching boxes or sleeves timed to the same launch. Clients ordering both now work to a single production timeline under one supplier.

For buyers, consolidating the two functions changes how a project is run. A client briefs one team and works to a single production timeline, so the gift item and the packaging it ships in are scheduled against the same delivery date instead of being tracked as two jobs. Colour matching and print finishing are handled within one production process, which keeps branding consistent between the item and the box it arrives in. Quality control covers both components at the same stage, and any delay sits with a single point of accountability. Volumes across gifts and packaging can be quoted together instead of being priced by two vendors working to separate minimum order quantities. For procurement teams, a single supplier also means one vendor record to maintain and one invoice per campaign, which is a practical consideration for government agencies and large corporations buying through GeBIZ, Ariba, or Coupa.

The Vietnam operation serves a dual function. Alongside supplying Vietnamese businesses through its local platform, the office gives The Gift Empire direct presence in one of the region’s largest manufacturing bases, where a significant share of the product it already sources is made. Vietnam’s electronics sector contributed over 35 per cent of the country’s total exports in 2025, reaching a record US$165 billion, according to Vietnam Briefing. Working on the ground allows closer collaboration with manufacturing partners and tighter oversight of production and quality control. The company expects this to shorten lead times for its Singapore and Malaysia clients and reduce its exposure to disruption in any single supply market.

Vincent Lau, Sales Manager at The Gift Empire, said the changes came out of client requests and not a shift in the company’s focus.

“Most of our work is still corporate gifting for clients here in Singapore, and that has not changed. What has changed is that more of them want one team handling the gifting and the packaging instead of coordinating two suppliers against the same deadline, because when the packaging runs late, the whole campaign moves with it. Vietnam happened at the same time for a practical reason, which is that a lot of the manufacturing we already source from is there, and being on the ground changes how quickly we can sort things out.” – Vincent Lau, Sales Manager, The Gift Empire Pte Ltd

The two developments give The Gift Empire a broader service range and a wider sourcing base within the same quarter, with Singapore continuing as the primary market for its corporate gifting and packaging work. The direction Lau has set out for the company is to operate as a single-source provider for corporate gifting and packaging across Southeast Asia, where a client in any of its markets briefs one team and works to one production timeline supported by a regional sourcing network.

Hashtag: #TheGiftEmpire

https://giftempire.com.sg/

The issuer is solely responsible for the content of this announcement.

About The Gift Empire

Founded in 1999, The Gift Empire Pte Ltd is a Singapore-based one-stop provider of customised corporate gifts, promotional gifts, and branded packaging. With more than 25 years of industry experience, the company supplies SMEs, multinational corporations, government agencies, educational institutions, banks, hotels, and event agencies, and is registered on GeBIZ, Ariba, and Coupa. Its services span sourcing, design, quality control, logistics, and fulfilment, with a catalogue of over 400 branded products available with custom logo application. The Gift Empire operates in Singapore, Malaysia, and Vietnam, and its packaging division, Packaging Empire, delivers bespoke packaging for corporate and retail applications.

The Malaysian Palm Oil Board has developed Sawit EcoTherm, a non-conductive dielectric fluid made largely from palm-derived materials that allows servers and other computing components to be immersed directly in coolant. The technology eliminates the need for conventional evaporative cooling towers and is being positioned for AI and hyperscale facilities where rising processor densities are producing substantially more heat.

Sawit EcoTherm remains at the pre-commercial stage, with pilot projects, technical validation and partnerships with data centre operators among the steps required before widespread deployment. Researchers say the fluid could reduce cooling-related energy consumption by about 30% to 50%, largely by removing server fans and transferring heat directly from electronic components.

MPOB estimates that conventional water-based cooling across Malaysia’s expanding data centre industry could eventually require as much as 876 million litres of water a day. Other projections based on currently identified developments are lower, illustrating the uncertainty surrounding future capacity and cooling configurations. Data centres planned across Selangor, Johor and Negeri Sembilan have been estimated to require more than 445 million litres daily if projected demand materialises.

The pressure is particularly acute in Johor, which has become one of Asia’s fastest-growing data centre clusters because of its proximity to Singapore, available industrial land and established power and connectivity infrastructure. Water availability and grid capacity have increasingly become constraints as developers seek to commission large AI facilities.

Malaysia’s data centre and cloud computing investment approvals reached RM144.4 billion between 2021 and the middle of 2025. Global technology and infrastructure groups including Microsoft, Amazon, Google, ByteDance, Equinix and AirTrunk have committed billions of dollars to expanding computing capacity in the country.

AirTrunk announced plans this year to invest about $3 billion in two additional hyperscale campuses in Johor, adding more than 280 megawatts of capacity. Equinix separately unveiled an investment exceeding $190 million for another Kuala Lumpur facility designed to support more than 2,200 cabinets and equipped for advanced liquid cooling.

Those developments are accelerating interest in alternatives to traditional air and water cooling. AI servers can generate several times more heat than conventional computing equipment, making direct liquid cooling and immersion systems increasingly attractive as rack power densities rise.

Sawit EcoTherm uses palm-derived ester formulations engineered to provide electrical insulation while absorbing heat from processors, memory, power supplies and graphics processing units. MPOB has developed two formulations, EcoTherm 5s and EcoTherm 8s, both with dielectric breakdown strength exceeding 75 kilovolts.

The fluids are designed for single-phase immersion systems, where coolant remains liquid while circulating through a closed loop. The 8s formulation has a minimum flash point of 200 degrees Celsius, while the 5s version has a minimum of 160 degrees. Their characteristics are intended to combine thermal performance with relatively low pumping requirements.

Palm-derived material can also offer a cost advantage. Commercial synthetic and petroleum-based immersion fluids can cost about RM50 to RM80 per kilogram, while the raw-material cost for producing the palm formulation has been estimated at roughly RM20 to RM25 per kilogram. Final commercial pricing has not been announced.

MPOB says up to 95% of the material used in Sawit EcoTherm can come from renewable bio-based sources. The formulations are biodegradable and free from PFAS, a class of persistent chemicals that has attracted growing regulatory scrutiny because of its resistance to environmental degradation.

The technology nevertheless carries broader sustainability questions because expansion of oil-palm cultivation has historically been associated with deforestation, biodiversity loss and pressure on wildlife habitats. The environmental case for palm-based coolant will therefore depend partly on traceable sourcing, lifecycle emissions and whether demand can be met without encouraging additional land conversion.

Immersion cooling itself is not new. Vegetable-derived, mineral-oil and synthetic dielectric fluids are already available, while many operators developing AI facilities favour direct-to-chip liquid cooling because it can be integrated into server architectures without fully submerging equipment. Commercial success for Sawit EcoTherm will depend on compatibility with hardware, long-term fluid stability, maintenance requirements and acceptance by server manufacturers.

2Q26 Business and Financial Highlights

• Bora delivered historically record-high quarterly revenues of NT$5,889 million in 2Q26, up 47.2% quarter-over-quarter driven by broad-based operational momentum, with basic EPS of NT$4.36.
• CDMO revenue growth and increased site utilization rates, along with strong growth in the rare disease business and a return to growth for generics business of the Pharma Sales operations lifted group profitability, with gross margin expanding to 41.3% from 36.0% and operating margin reaching 16.8% from 10.2% in 1Q26. Excluding one-time costs related to the Weider Global Nutrition transaction, operating margin was approximately 18%.
• CDMO’s strong backlog of US$317 million as of end of 2Q26, another historical high following a strong quarter, signals that Bora’s core business continued to perform with higher demand.
• Pharma Sales’ rare disease franchise continues to show double digit sequential growth and the increased demand from government channels during the quarter with stabilized pricing in DLS has lifted the generics business back to normal.
• Reflecting Bora’s recent increase in investment in Sunway Biotech, from 35.97% to 42.27% and subsequent acquisitions of Weider Global Nutrition’s, the Company has introduced “Consumer Healthcare (CHC)” as a new segment in its revenue mix disclosure beginning this quarter. In 2Q26, revenues from CHC were NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY, and contributed to 14% of the Bora Groups consolidated revenues, an all-time high.
• Cash-on-hand reached an all-time high of NT$8,431 million as the Company was preparing for MacroGenics Inc.’s Rockville facility acquisition.
• The Company has kicked off a group-wide AI in Manufacturing, BORA AIM, program aimed at improving process efficiency across sites, spanning engineering, quality and production. Bora has also signed a partnership with Insilico Medicine for AI drug discovery. The first 6 months will focus on beta version testing of the Bora AIM agents and AI champions to drive process consolidation.
• Share capital increased 0.3% during the quarter from employee stock option exercise.

Mr. Bobby Sheng, Chairman of Bora Group, stated, “We are pleased to announce Bora Group’s return to strong operating profits and double to triple-digit growth on all key margins sequentially, as well as demonstrate that our soft 1Q26 performance was anomalous rather than structural. Our impressive sequential improvement was driven entirely by strong demand from both our CDMO and Pharma Sales businesses, with 2Q26 manufactured batches reaching 0.38 billion doses, led by increased commercial production in Maple Grove and Zhunan sites and a full quarter of operations in the Maryland injectable facility, while our flagship products DLS and VIGAFYDE® in Pharma Sales continues to secure leading market share.

Our focus right now is execution. CAPEX investments in our mature sites, including facilities in Taiwan and in Canada, continue to deliver operational leverage driven by gross margin expansion, and our recently acquired oral solid dose facility in Maple Grove continues to show stellar and impactful demand as we sign more projects. Our 12-month rolling backlog is at historic high in almost all our sites, despite projected manufacturing delays at our Maryland injectable facility as we diligently respond to FDA audit observations from a recent audit. Bora Group’s commitment to the fast-growing Biologics manufacturing industry took another big step as we look to integrate 12,000 liters of capacity, and 3 commercial products from our Rockville facility, as well as see revenue recognition from this acquisition starting Q3. As Bora’s CDMO footprint expands in the US, we continue to capture durable, high-value demand as customers increasingly prioritize supply security and onshore capacity.

In addition, we are seeing sustained growth and improved gross margins in the Vigabatrin franchise, our most important, rare disease franchise, thanks to renegotiations with our partner vendors. Accelerated state and government orders for generics products increased 2Q26 revenues and 6 new generics launches have also supported a more diversified generics portfolio. Together, the advancement in rare disease franchise and generics business has positioned Bora’s Pharma Sales business, operating under the name Upsher-Smith, in a far stronger state than it was just a quarter ago.

As announced in July, we are excited to be developing a group-wide AI in Manufacturing program, BORA AIM, aimed at improving process efficiency across sites, spanning engineering, quality and production. We also announced a partnership with Insilico Medicine to enhance our understanding of AI drug discovery and create more customized AI manufacturing platforms for AIDD small molecules. In the next 12 months, Bora Group will be ready to showcase some exciting AI-enabled CDMO platforms that will truly add value to our partners and sharpen the overall competitive advantages of Bora Group.

As our momentum carries Bora into the second half of the year, we expect margins of our flagship products in Pharma Sales and CHC businesses to hold steady on continuous revenue growth, and improved efficiencies in the CDMO business in addition to consolidation of new revenues from the Rockville facility.”

2Q26 Operational Achievements & 2026 Outlook

Global CDMO Operations

Revenues increased 30.3% year-over-year and 29.0% quarter-over-quarter including internal orders, and 33.0% and 40.2% external orders only, or NT$2,116.4 million. The growth was primarily driven by a strong rebound in injectables following the semi-annual maintenance in 1Q26 and same period last year, and demand acceleration overall as we continue to meet the increasing backlog.

CDMO business also signed a record high US$378.2 million in total external wins. Highlighted by a 10+2-year, multi product commercial contract in our Maple Grove facility with a new top-20 pharma company, and 14 new molecules from pre-commercial programs from multiple new customers. Bora is confident in its mid- to long-term growth trajectory as pharma and biotech companies continue to look for US based CDMOs as a part of their efforts to onshore US production and improve supply chain resilience.

During the quarter, 0.38 billion doses, or 109 molecules, were developed and manufactured. Contribution from the top 20 global pharmaceutical companies stood at roughly 30% and should increase drastically in the next 8 quarters.

Looking at 3Q26, the Company is highly optimistic, with our backlog having climbed to an unprecedented level even after a strong quarter of manufacturing output. We do anticipate some timing shifts in revenue recognition related to scheduled semi-annual maintenance at our Maryland injectable site, alongside targeted quality-enhancement activities in connection with observations on passive RABS (Restricted Access Barrier System) line received from an FDA audit that took place 2Q26. However, there has been no reduction in total commercial batch productions in 2026 as we speak and several existing clients have initiated transfers to the FlexPro isolator filling lines. RFP activity has risen, with the first GMP PPQ campaign starting in August. On the newest, isolator-based AST lines, factory acceptance testing (FAT) is planned for Q326, with qualification to follow in 2027, expanding our ability to onboard small-scale isolator programs, including tech transfers.

On biologics, Rockville facility revenue recognition started in the first month of 3Q26 and the site has confirmed that it is on track to deliver batch production volumes ahead of last year’s run rate of around 13 batches for the remainder of 2026. We anticipate one-time transaction costs from this acquisition of approximately 3% of the purchase price including legal and FA fee and transition related expenses as stated in the Transition Service Agreement. The Rockville acquisition expands biologics capacity and brings integrated drug substance (DS) and drug product (DP) capabilities under one roof, strengthening our end-to-end service offering and attracting more inbound opportunities and higher value conversion with cross selling opportunities for our injectable business.

For our strategic investment in Tanvex Biopharma, the main Bora Biologics platform company, although the business still operates at a loss, Tanvex has built a strong presence in international conferences, especially Bio International in the US in June. We have seen a positive uptick in pipeline from leading biotechs and heavy weight biopharmas, and stable demand for early-stage PD programs in Zhubei. The Rockville acquisition is expected to orchestrate and accelerate opportunities for Tanvex in the coming quarters.

Pharma Sales Operations

Revenues decreased 2.7% year-over-year and increased 30.4% quarter-over-quarter, arriving at NT$2,934.04 million in 2Q26. The year-over-year decrease was mainly due to a product rationalization program in 2025 that lead to the withdrawal of a basket of legacy generics products.

During the quarter, specialty and brand came in strongly, up 58.8% for the quarter QoQ and displayed almost 50% growth against 2025 run rate. The rare-disease Vigabatrin franchise demand is robust, and our continuous investment in the segment has resulted in much broader patient access compared to when we acquired Upsher-Smith 28 months ago. On coverage, we are on track to achieve year-end formulary goal of >50%, supported by more regional plans and strong physician adoption as they gain experience with VIGAFYDE®. The Company has also renegotiated contracts with suppliers, leading to improved gross margins for the franchise during the quarter and expects full economic contribution starting 3Q26. Simultaneously, the Company out-licensed its non-core assets, Stiripentol generics and 505(b)(2), during the quarter, fully capturing the economic value of these drug assets to enable fueled and renewed focus on core specialty and brand business.

The generics business returned to stability as Upsher-Smith successfully defended flagship product DLS. High value generics advanced 20.6% sequentially from downstream restocking, narrowing the year-to-date YoY decline against 2025 run rate to high teens.

Having executed our way through specialty and brand business growth and generics portfolio optimization, we have returned to the 2023–2024 peaks of Pharma Sales performance but with healthier and more resilient operating profits. As of now, Upsher-Smith sees 6 ANDA pending approval.

CHC Operations

Bora Group has increased holdings of Sunway Biotech to 42.27% through a private placement at $NT 596 million. Subsequently, Sunway completed the acquisition of Weider Global Nutrition (WGN), a global nutritional supplements company with offices in the US, Spain, and Germany and products sold in over 60 countries. Benefitting from the consolidation of WGN that started in May, Consumer Health business totaled NT$824.76 million in 2Q26, a 354.4% increase QoQ and 234.3% YoY. Focusing on longevity and sports nutrition, WGN’s distribution strength is expected to meaningfully contribute to the CHC business in 2026 and beyond and shall deliver vertical-integration synergies to Sunway’s existing ingredients’ manufacturing operations. Together, the WGN acquisition is expected to catapult Sunway Biotech into a leading global nutritional supplements company and substantially accelerate top and bottom-line improvements in the future.

Recent Investor Conference

Bora will host English online earnings call at 8:00 a.m. Taiwan time on Aug. 14^th, 2026. The event will cover the Company’s 2Q26 financial and business results and 2H26 outlook.

English Online Earnings Presentation Link: https://teams.microsoft.com/meet/225504163505748?p=UyyncWl1CnOzjBCNKD

Bora will participate in Goldman Sachs 2026 CDMO day in Singapore in Sept. For 1:1 meetings with management, please contact your GS representative.

Bora 2026 Earnings Schedule

Q3 2026: Expected in the 2^nd week of Nov 2026
Q4 2026: Expected in the 2^nd week of Mar 2027

Hashtag: #BoraGroup

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.